Sterile Compounding(无菌复合)研究综述
Sterile Compounding 无菌复合 - Details on facilities' parenteral admixture infrastructure, policy for and provision of sterile compounding, and pharmacy department human resources, including composition and staffing ratios, were also collected. [1] Non-sterile to sterile compounding is often associated with risks of inaccuracies, impurities, and contamination. [2] The PPE requirement for sterile compounding and need to maintain supplies within the pharmacy cleanroom are often overlooked. [3] Nonsterile compounding is a fundamental component of pharmacy practice, and compounded medications are sometimes essential to optimize a patient's medication therapy. [4] TNAs were compounded by pharmacists in a standard way following "four factors of sterile compounding". [5]还收集了有关设施的肠外混合基础设施、无菌复合的政策和提供以及药房部门人力资源的详细信息，包括组成和人员配备比例。 [1] 非无菌到无菌的混合通常与不准确、杂质和污染的风险有关。 [2] 对无菌复合的 PPE 要求以及在药房洁净室内维持供应的需要经常被忽视。 [3] 非无菌复合是药学实践的基本组成部分，复合药物有时对于优化患者的药物治疗至关重要。 [4] TNA由药剂师按照“无菌配制的四个因素”以标准方式配制。 [5]
sterile compounding training
Conclusions Combined MFT-F, as a part of a comprehensive sterile compounding training program, appeared as a convenient and promising tool to increase both the sterile compounding safety and awareness of radioactive contamination in radiopharmacy. [1] Purpose: The purpose of the study is to develop and implement a standardized sterile compounding training program in a multihospital system that incorporates sterile compounding best practice recommendations and ensures compliance with United States Pharmacopeia (USP) Chapters 797 and 800 standards. [2]结论 联合 MFT-F 作为综合无菌配制培训计划的一部分，似乎是一种方便且有前景的工具，可提高放射性药物中的无菌配制安全性和放射性污染意识。 [1] 目的：该研究的目的是在多医院系统中开发和实施标准化的无菌复合培训计划，该计划包含无菌复合最佳实践建议，并确保符合美国药典 (USP) 第 797 章和第 800 章标准。 [2]
sterile compounding environment
Based on increasing regulatory demands and documentation gaps identified, solutions were explored in the pharmacy's nonsterile compounding environment. [1] ” While the authors certainly recognize the risks associated with sterile compounding, we also maintain that compounding a preparation into its packaging for administration (a syringe) in a sterile compounding environment replete with specialized resources and expert practitioners is preferable to the alternative of nonsterile preparation of intracameral injections in the operative suite. [2]基于日益增加的监管要求和确定的文件差距，在药房的非无菌复合环境中探索了解决方案。 [1] ” 虽然作者当然认识到与无菌复合相关的风险，但我们也认为，在充满专业资源和专业从业人员的无菌复合环境中将制剂复合到其包装（注射器）中优于非无菌制剂的替代方案。手术室前房内注射。 [2]